Our Full Year 2025 results show a return to NAV growth, with NAV per share up 13% to 110.4p. We have also highlighted the opportunity for significant potential future royalty income, as the Group benefits from financial exposure to Pfizer’s obesity drug franchise.
Having raised £68m in 2025 from exits, the Group has confirmed its target of delivering more than £250m of exits between 2025 and the end of 2027. The Group remains financially strong, closing the year with £211m of gross cash.
We’re building a better future, one investment at a time
We’re building a better future, one investment at a time
We’re building a better future, one investment at a time
We’re building a better future, one investment at a time
We partner with innovators with limitless potential
Building a healthier, tech-enriched, regenerative future
Our HealthTech team are working towards a healthier future with a view to curing and preventing disease rather than simply treating symptoms. In doing so, its ambition is to help ensure people are living healthier, rather than just longer, lives.
Building a healthier, tech-enriched, regenerative future
Our DeepTech team are working towards a tech-enriched future by investing in assets that will enable digital resilience, create prosperity and enable new human capability. We target differentiated, defensible innovations with a strong value proposition and the potential to disrupt a multibillion-dollar global market.
Building a healthier, tech-enriched, regenerative future
Our CleanTech team are working towards a regenerative future by investing in companies that address the global climate challenge. We target innovators creating scalable climate technology solutions.
Not only do we generate strong financial returns, but our investments have a positive social and environmental impact and align closely with the UN’s Sustainable Development Goals.
Turning radical thinking into tangible impact
Our team works at the cutting edge of HealthTech, DeepTech and CleanTech: we’re scientists, innovators and practitioners with a wealth of relevant in-field experience and insight.
